Tuberculosis and HIV - Features of the co-infection;TB und HIV-Besonderheiten der Ko-infektion

Therapeutische Umschau

Volumn 68, Issue 7, 2011, Pages 389-394

  Lüthi, Beatrice ^a   Diacon, Andreas H ^b  

^a Madwaleni Hospital   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MICROSCOPY; MIXED INFECTION; PATIENT COMPLIANCE; REVIEW; SPUTUM SMEAR; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COMORBIDITY; CROSS-CULTURAL COMPARISON; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; HUMANS; MASS SCREENING; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 79960066457     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000182     Document Type: Review

References (19)

1. Global Plan to Stop TB 2011-2015. 2010. (Accessed 26.10.2010, 2010, at http://www.stoptb.org/global/plan/.
2. Schutz C, Meintjes G, Almajid F, Wilkinson RJ, Pozniak A. Clinical management of tuberculosis and HIV-1 co-infection. Eur Respir J 2010; 36: 1460-1481.
3. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis 2010; 14: 1295-1302.
4. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-1751.
5. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40: 1500-1507.
6. Were W, Moore D, Ekwaru P, et al. A simple screening tool for active tuberculosis in HIV-infected adults receiving antiretroviral treatment in Uganda. Int J Tuberc Lung Dis 2009; 13: 47-53.
7. Cattamanchi A, Dowdy DW, Davis JL, et al. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis 2009; 9: 53.
8. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid mo lecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792.
9. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-10.
10. Cattamanchi A, Ssewenyana I, Davis JL, et al. Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infect Dis 2010; 10: 75.
11. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month shortcourse therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32: 623-62.
12. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis coinfected patients who received rifampicin. HIV Med 2008; 9: 294-294
13. L'Homme R F, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 23: 863-865.
14. Marais S, Wilkinson RJ, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 2009; 6: 162-171.
15. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
16. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrugresistant tuberculosis: the perfect storm. J Infect Dis 2007; 196 Suppl 1: S86-S107.
17. Samandari T. Randomized, Placebo Controlled Trial of 6 vs 36 months of Isoniazid TB Preventative Therapy for HIV-infected Adults in Botswana. In: 17th Conference on Retrovirusses and Opportunistic Infections. San Francisco, United States of America; 2010.
18. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
19. Hesseling AC, Caldwell J, Cotton MF, et al. BCG vaccination in South African HIV-exposed infants-risks and benefits. S Afr Med J 2009; 99: 88-91.